Company intelligence / Profile preview

Aj Cell Point

Ownership: Private
Development stage: Commercial

Overview

CellPoint developed a decentralized T-cell manufacturing platform that allows for administration of fresh CAR-T products with a median vein-to-vein time of 7 days. After acquisition by Galapagos, clinical trials were progressing for CD19 CAR-T candidates in rrNHL and rrCLL/SLL with Phase 1 topline results expected around mid-2023.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapies
Industry: Biotech

Partnerships

Lonza (for Cocoon® platform)

Beyond the preview

Go deeper on Aj Cell Point.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aj Cell Point.

Explore the full profile